Evidence map›Paper›PMID 35593226›Full record

ArticleCancer medicine2022

Identifying tumor antigens and immuno-subtyping in colon adenocarcinoma to facilitate the development of mRNA vaccine.

Huaicheng Tan, Ting Yu, Chunhua Liu, Yang Wang, Fangqi Jing, Zhenyu Ding, Jiyan Liu, Huashan Shi

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Huaicheng TanDepartment of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
Ting YuDepartment of Pathology and Laboratory of Pathology, State Key Laboratory of Biotherapy, West China Hospital, West China School of Medicine, Sichuan University, Chengdu, China.
Chunhua LiuDepartment of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
Yang WangDepartment of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
Fangqi JingState Key Laboratory of Oral Diseases, National Clinical Research Center for Oral Diseases, West China Hospital of Stomatology, Sichuan University, Chengdu, China.
Zhenyu DingDepartment of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
Jiyan LiuDepartment of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.ORCID https://orcid.org/0000-0003-4885-5481
Huashan ShiDepartment of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.ORCID https://orcid.org/0000-0002-9958-9892
Sichuan University · CN

Funding

China Postdoctoral Science Foundation 2020M680150National Natural Science Foundation of China 82003195
6 · The paper itself

Abstract

The mRNA vaccine has provided a promising approach for cancer immunotherapies. However, only a few mRNA vaccines have been developed against colon adenocarcinoma (COAD). Screening potential targets for mRNA vaccines from numerous candidates is a substantial challenge. Considering the tumor heterogeneity, only a subset of patients might respond to vaccinations. This study was conducted to identify potential candidates for mRNA vaccines, and distinguish appropriate subgroups of COAD patients for vaccination. A total of five tumor antigens with prognostic values were identified, including IGF2BP3, DPCR1, HOXD10, TRIM7, and ZIC5. The COAD patients were stratified into five immune subtypes (IS1-IS5), according to consensus clustering analysis. Higher tumor mutation burden (TMB) was observed in IS1 and IS5 subtypes. The IS1 and IS5 subtypes have shown the baseline of immune-hot tumor microenvironment, while other subtypes displayed immune desert phenotype. Distinct expressions of immune checkpoints (ICPs)-related genes and immunogenic cell death (ICD) modulators were observed among five immune subtypes. Finally, the immune landscape was conducted to narrow the immune components for better personalized mRNA-based vaccination. The IFIT3, PARP9, TAP1, STAT1, and OAS2 were confirmed as hub genes, and COAD patients with higher expressions of these genes might be more appropriate for mRNA vaccination. In conclusion, the IGF2BP3, DPCR1, HOXD10, TRIM7, and ZIC5 were identified as potential candidates for developing mRNA vaccines against COAD, and patients in IS1 and IS5 subtypes might respond better to mRNA vaccination.

Indexed as

AdenocarcinomaColonic NeoplasmsAntigens, NeoplasmDNA-Binding ProteinsHumansmRNA VaccinesRNA, MessengerTranscription FactorsTripartite Motif ProteinsTumor MicroenvironmentUbiquitin-Protein LigasesAntigens, NeoplasmDNA-Binding ProteinsmRNA VaccinesRNA, MessengerTranscription FactorsTRIM7 protein, humanTripartite Motif ProteinsUbiquitin-Protein LigasesZIC5 protein, humancolon adenocarcinomaimmune landscapeimmune subtypesmRNA vaccinetumor antigens

Identifiers

PMID35593226
PMCPMC9741973
OpenAlexW4281262832

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.